Back to Search
RICHARD ORLOWSKI, DMD
DMD
Dentist
NPI: 1679624324Individual
Specialties, Licenses & Credentials
DentistPrimary
Dentist
Code: 122300000X
4446(NC)
Research & Publications (20)
Proteasome inhibitors in cancer therapy: lessons from the first decade.
PMID 18347166·Clin Cancer Res·2008
6-review
Altered editing in cyclic nucleotide phosphodiesterase 8A1 gene transcripts of systemic lupus erythematosus T lymphocytes.
PMID 18462347·Immunology·2008
8-other
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
PMID 17679727·J Clin Oncol·2007
3-trial
Is bortezomib superior to high-dose dexamethasone for the treatment of relapsed multiple myeloma?
PMID 16407873·Nat Clin Pract Oncol·2006
8-other
Targeting the proteasome as a therapeutic strategy against haematological malignancies.
PMID 16433592·Expert Opin Investig Drugs·2006
6-review
Initial therapy of multiple myeloma patients who are not candidates for stem cell transplantation.
PMID 17124081·Hematology Am Soc Hematol Educ Program·2006
6-review
The ubiquitin proteasome pathway from bench to bedside.
PMID 16304384·Hematology Am Soc Hematol Educ Program·2005
8-other
Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.
PMID 15626743·Blood·2005
3-trial
Oral valacyclovir as prophylaxis against herpes simplex virus reactivation during high dose chemotherapy for leukemia.
PMID 15512809·Leuk Lymphoma·2004
3-trial
Bortezomib and its role in the management of patients with multiple myeloma.
PMID 15056047·Expert Rev Anticancer Ther·2004
6-review
Successful pregnancy after cladribine therapy for hairy cell leukemia.
PMID 15061219·Leuk Lymphoma·2004
5-case
The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer.
PMID 12559038·Breast Cancer Res·2003
6-review
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.
PMID 12431963·J Clin Oncol·2002
3-trial
Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis.
PMID 12023956·J Biol Chem·2002
8-other
Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma.
PMID 19436606·Ther Clin Risk Manag·2009
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2304 S MIAMI BLVD, SUITE 126
DURHAM, NC 27703 - Phone
- (919) 361-9600
Quick Facts
- NPI
- 1679624324
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile